Verification of a Decision Analytic Model Assumption Using Real-world Practice Data: Implications for the Cost Effectiveness of Cyclo-oxygenase 2 Inhibitors (COX-2s)ByRobert Valuck, PhD, RPH. Author Reply by Emily R. Cox, PhD,Brenda Motheral, PhD,Doug Mager, BSApril 1st 2004
Improving Cancer Screening Adherence: Using the "Teachable Moment" as a Delivery Setting for Educational InterventionsByRuth C. Carlos, MD, MS,A. Mark Fendrick, MDApril 1st 2004
Population-Based Hepatitis C Surveillance and Treatment in a National Managed Care OrganizationByDeborah Shatin, PhD,Stephanie D. Schech, MPH,Keyur Patel, MD,John G. McHutchison, MDApril 1st 2004
Malpractice Prevention, Patient Safety, and Quality of Care: A Critical LinkageByL. Gregory Pawlson, MD, MPH,Margaret E. Oâ??Kane, MSApril 1st 2004
Comparing Breast Cancer Case Identification Using HMO Computerized Diagnostic Data and SEER DataBySharon J. Rolnick, PhD, MPH,Gene Hart, MS,Mary B. Barton, MD, MPP,Lisa Herrinton, PhD,Sharon Kaufer Flores, MS,Kristi J. Paulsen, BA,Gail Husson, MPH, MEd,Emily L. Harris, PhD, MPH,Ann M. GeigApril 1st 2004
Health Plan Policies and Programs for Colorectal Cancer Screening: A National ProfileByCarrie N. Klabunde, PhD,Gerald F. Riley, MSPH,Margaret T. Mandelson, PhD,Paul S. Frame, MD,Martin L. Brown, PhDApril 1st 2004
Primary Care Practice and Facility Quality Orientation: Influence on Breast and Cervical Cancer Screening RatesByCaroline Goldzweig, MD, MSHS,Patricia H. Parkerton, PhD, MPH,Donna L. Washington, MD, MPH,Andrew B. Lanto, MA,Elizabeth M. Yano, PhDApril 1st 2004
